Catalytic Antibodies May Contribute to Demyelination in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Jensen, Michael Anthony, Dafoe, Miranda Lee, Wilhelmy, Julie et al. · Biochemistry · 2024 · DOI
Quick Summary
Researchers found that some ME/CFS patients may have special antibodies in their blood that can break down myelin, the protective coating around nerves. This breakdown could explain nerve pain and muscle weakness in ME/CFS. The study also showed that a drug already approved for multiple sclerosis might be able to stop this harmful antibody activity.
Why It Matters
Identifying catalytic antibodies that damage myelin offers a potential mechanistic explanation for neurological symptoms in ME/CFS and suggests existing MS treatments might be repurposed as therapeutic candidates. This research could redirect treatment development toward immune modulation strategies and provides a testable biological hypothesis for a condition that currently lacks clear pathophysiologic mechanisms.
Observed Findings
Catalytic autoantibodies capable of degrading myelin basic protein were isolated from ME/CFS patient plasma samples.
Aprotinin, a serine protease inhibitor, specifically prevented MBP breakdown while other protease inhibitor classes did not.
MR imaging findings in ME/CFS patients show white matter disease consistent with demyelination.
COVID-19 has been reported as a trigger for ME/CFS onset and is associated with demyelination.
Inferred Conclusions
Catalytic antibodies with serine protease-like activity may contribute to demyelination in ME/CFS.
Existing MS immunomodulators may have therapeutic potential for ME/CFS through inhibition of these pathogenic antibodies.
Demyelination could be a significant pathophysiologic mechanism in ME/CFS, potentially explaining white matter abnormalities and neurological symptoms.
Remaining Questions
Are these catalytic antibodies present in all ME/CFS patients or only a subset, and do they correlate with symptom severity?
Do healthy controls and other neurological disease patients also have these antibodies, and if so, what distinguishes the pathogenic activity in ME/CFS?
What This Study Does Not Prove
This preliminary study does not establish that catalytic antibodies are present in all ME/CFS patients or that they are the primary cause of the disease. It does not demonstrate clinical efficacy of glatiramer acetate or aprotinin in ME/CFS patients, nor does it prove causation between these antibodies and symptoms—only that they have the capacity to degrade myelin. The presence of these antibodies in healthy controls was not addressed.
Tags
Symptom:PainFatigue
Biomarker:AutoantibodiesNeuroimaging
Phenotype:Infection-Triggered
Method Flag:PEM Not DefinedNo ControlsSmall SampleExploratory Only
Would glatiramer acetate or other serine protease inhibitors improve symptoms in ME/CFS patients, and what would be the optimal dosing and patient selection?
What triggers the production of these catalytic antibodies, and are they directly involved in post-COVID ME/CFS specifically?